Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2022 Earnings Call Transcript

Page 9 of 9

Michael Riad: Thank you.

Operator: I show no further questions at this time. I would now like to turn the conference back to David Meeker for closing remarks.

David Meeker: Great. Well, thanks everyone for tuning in. As you’ve heard, we remain incredibly encouraged by initial experience on BBS. The R&D programs are up and running now and executing, so we feel good about that area. And excited about a new opportunity. We’ll spend an opportunity to Rhythm and Xinvento and look forward to updating on that. So that will sign up. Thanks again.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.

Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)

Page 9 of 9